Suspension of Shares
24 7월 2009 - 11:50PM
UK Regulatory
TIDMAZM
RNS Number : 2750W
Alizyme PLC
24 July 2009
+---------------------------------------+---------------------------------------+
| FOR IMMEDIATE RELEASE | 24 JULY 2009 |
+---------------------------------------+---------------------------------------+
ALIZYME PLC
SUSPENSION OF SHARES FOR TRADING ON THE OFFICIAL LIST, COMPANY TO BE PLACED INTO
ADMINISTRATION
Alizyme plc (LSE: AZM) ("Alizyme" or the "Company")
Cambridge UK, 24 July 2009: Alizyme PLC announces that, at its own request,
trading in the Company's ordinary shares has been suspended with effect from
3.30 pm on 24 July 2009, following which the Board has agreed to appoint Ian
Carr and Nigel Morrison of Grant Thornton UK LLP to act as Administrators of the
Company.
On 29 June 2009, the Company announced in a trading update that it did not
expect to have sufficient funding to last beyond the end of August 2009 and that
it would be unable to continue as a going concern without urgently raising
additional funds. As part of the trading update, the Company also announced that
it was in discussions with its commercial partners to mitigate potential
increased funding obligations under its licensing and development agreements
with regard to COLAL-PRED .
The Company was today notified by Prometheus Laboratories Inc ("Prometheus")
that a complaint had been filed with the United States District Court, Southern
District of California, regarding an alleged breach of a Licence Agreement
between Prometheus and Alizyme Therapeutics Limited, a wholly owned subsidiary
of Alizyme. The complaint was filed on 21 July 2009, but has not been served on
Alizyme Therapeutics Limited or Alizyme.
The Company no longer believes that it will be able to conclude successfully the
discussions with its commercial partners, and therefore does not believe that
refinancing of the Company could now be completed, within a timeframe during
which the Company would have sufficient cash reserves to continue trading.
As a result, the Board of Alizyme has taken advice and with great regret no
longer believes that the Company is in a position to continue its operations. It
is expected that the appointment of Administrators will take place either today
or on Monday 27 July 2009, following which the Administrators will take such
measures as they believe appropriate, including seeking a buyer for the Company
and/or its assets.
The Board of Directors of Alizyme Therapeutics Limited ("ATL") has also agreed
to appoint the above named persons from Grant Thornton UK LLP to act as
administrators of ATL.
In addition, the Annual General Meeting, which had been convened for 12.00 pm on
Wednesday, 29 July 2009, will no longer take place.
For further information please call:
Ian Carr
Grant Thornton UK LLP
Byron House
Cambridge Business Park
Cambridge
CB4 0WZ
Telephone: +44 (0) 1223 225600
Email: ian.carr@gtuk.com
Press Enquiries:
Cathy Connan
PR and Communication
Connan Limited
Telephone: +44 (0) 7976 669089
Email: cathy@cathyconnan.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
SRSUSSSRKSRBUAR
Alizyme (LSE:AZM)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Alizyme (LSE:AZM)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Alizyme (London Stock Exchange)의 실시간 뉴스: 최근 기사 0
More Alizyme News Articles